Advertisement

Non-Erosive Reflux Disease (NERD) and Functional Heartburn

  • E. M. M. Quigley

Conclusion

NERD is a real entity and its importance in the spectrum of GERD must be appreciated. Functional heartburn needs to be further differentiated as that subgroup of patients in which there appears to be no relationship between symptoms, albeit “typical” of GERD, and acid exposure. Several aspects of NERD need to be appreciated including the overlap with functional dyspepsia and potential differences in response to such therapeutic interventions as acid suppressive therapy and fundoplication. While definitive studies on this issue are yet to be completed, it remains quite possible that our failure to separate functional heartburn from NERD, in general, has contributed in large measure to diagnostic difficulties and therapeutic disappointment in GERD. This author contends that functional heartburn should be removed from the spectrum of GERD and relocated to the functional gastrointestinal disorders; only then will effective approaches to the assessment and therapy of this challenging disorder emerge.

Keywords

Irritable Bowel Syndrome Functional Dyspepsia Acid Exposure GERD Patient Esophageal Acid Exposure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Spechler SJ (1992) Epidemiology and natural history of gastroesophageal reflux disease. Digestion 51(Suppl 1): 24–29PubMedCrossRefGoogle Scholar
  2. [2]
    Smout AJPM (1997) Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 11(Suppl 2): 81–85Google Scholar
  3. [3]
    Lind T, Havelund T, Carlsson R et al (1997) Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 32: 974–979PubMedGoogle Scholar
  4. [4]
    Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ (1999) An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 44(Suppl 2): S1–S16CrossRefGoogle Scholar
  5. [5]
    Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberod G, Carlsson R, Junghard O (1999) On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis — a placebo-controlled randomized trial. Aliment Pharmacol Ther 13: 907–914PubMedCrossRefGoogle Scholar
  6. [6]
    Tew S, Jamieson GG, Pilowsky I et al (1997) The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis Esophagus 10: 9–15PubMedGoogle Scholar
  7. [7]
    Tummala V, Barwick KW, Sontag SJ, Vlahcevic RZ, McCallum RW (1987) The significance of intraepithelial eosinophils in the histologic diagnosis of gastroesophageal reflux. Am J Clin Path 87: 43–48PubMedGoogle Scholar
  8. [8]
    Schindlbeck NE, Wiebecke B, Klauser AG, Voderholzer WA, Muller-Lissner SA (1996) Diagnostic value of histology in non-erosive gastroesophageal reflux disease. Gut 39: 151–154PubMedGoogle Scholar
  9. [9]
    Fass R, Fennerty MB, Vakil N (2001) Non-erosive reflux disease (NERD) — current concepts and dilemmas. Am J Gastroenterol 96: 303–314PubMedGoogle Scholar
  10. [10]
    Watson RGP, Tham TCK, Johnston BT, McDougall NI (1997) Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux — the “sensitive oesophagus”. Gut 40: 587–590PubMedGoogle Scholar
  11. [11]
    Johnston BT, Lewis SA, Collins JSA et al (1997) Acid perception in gastro-oesophageal reflux disease is dependent on psychological factors. Scand J Gastroenterol 32: 974–979Google Scholar
  12. [12]
    Clouse RE, Richter JE, Heading RC, Janssens J, Wilson JA (1999) Functional esophageal disorders. Gut 45(Suppl II): II31–II36PubMedCrossRefGoogle Scholar
  13. [13]
    Smout AJPM (1997) Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 11(Suppl 2): 81–85Google Scholar
  14. [14]
    Kahrilas PJ (2004) Review article: gastro-oesophageal reflux disease as a functional gastrointestinal disorder. Aliment Pharmacol Ther 20(Suppl 7): 50–55PubMedCrossRefGoogle Scholar
  15. [15]
    Tack J, Janssens J (2002) Functional heartburn. Curr Treat Options Gastroenterol 5: 251–258PubMedGoogle Scholar
  16. [16]
    Fass R (2000) Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 18: 20–26PubMedCrossRefGoogle Scholar
  17. [17]
    Schenk BE, Kuipers EJ, Klinkenberg-Knol EC et al (1997) Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 92: 1997–2000PubMedGoogle Scholar
  18. [18]
    Johnsson F, Weywadt L, Solhaug J-H et al (1997) One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 33: 15–20CrossRefGoogle Scholar
  19. [19]
    Fass R, Ofman JJ, Gralnek IM et al (1999) Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 159: 2161–2168PubMedCrossRefGoogle Scholar
  20. [20]
    Fass R, Tougas G (2002) Functional heartburn: the stimulus, the pain, and the brain. Gut 51: 885–892PubMedCrossRefGoogle Scholar
  21. [21]
    Dent J (1998) Gastro-oesophageal reflux disease. Digestion 59: 433–445PubMedCrossRefGoogle Scholar
  22. [22]
    Trimble KC, Pryde A, Heading RC (1995) Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 37: 7–12PubMedGoogle Scholar
  23. [23]
    Shi G, des Varannes SB, Scarpignato C, Le Rhun M, Galmiche JP (1995) Reflux related symptoms in patients with normal esophageal exposure to acid. Gut 37: 457–464PubMedGoogle Scholar
  24. [24]
    Fass R, Naliboff B, Higa L et al (1998) Differential effect of long-term esophageal acid exposure on mechano-sensitivity and chemo-sensitivity in humans. Gastroenterology 115: 1363–1373PubMedCrossRefGoogle Scholar
  25. [25]
    Talley NJ, Zinsmeister AR, Schleck CK, Melton III LJ (1992) Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 102: 1259–1268PubMedGoogle Scholar
  26. [26]
    Quigley EMM (1997) Motility, heartburn and dyspepsia. Aliment Pharmacol Ther 11(Suppl 2): 41–50Google Scholar
  27. [27]
    DiBaise JK, Lof J, Akromis I, Quigley EMM (1999) An open-label comparison of omeprazole and cisapride in endoscopy-negative reflux disease. Am J Gastroenterol 94: A2583Google Scholar
  28. [28]
    Hopwood D, Milne G, Logan KR (1979) Electron microscopic changes in human oesophageal epithelium in oesophagitis. J Pathol 129: 161–167PubMedCrossRefGoogle Scholar
  29. [29]
    Carney CN, Orlando RC, Powell DW, Dotson MM (1981) Morphologic alterations in early acid-induced epithelial injury of the rabbit esophagus. Lab Invest 45: 198–208PubMedGoogle Scholar
  30. [30]
    Tobey NA, Carson JL, Alkiek RA, Orlando RC (1996) Dilated intracellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 111: 1200–1205PubMedCrossRefGoogle Scholar
  31. [31]
    Pace F, Santalucia F, Bianchi Porro G (1991) Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut 32: 845–848PubMedGoogle Scholar
  32. [32]
    Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA (1992) Three-year follow-up of patients with gastro-esophageal reflux disease. Gut 33: 1016–1019PubMedGoogle Scholar
  33. [33]
    Ollyo JB, Monnier P, Fontolliet C et al (1993) The natural history, prevalence and incidence of reflux oesophagitis. Gullet 3(Suppl): 3–10Google Scholar
  34. [34]
    Kuster E, Ros E, Toledo-Pimentel V et al (1994) Predictive factors of the long-term outcome in gastro-oesophageal reflux disease: six-year follow-up of 107 patients. Gut 35: 8–14PubMedGoogle Scholar
  35. [35]
    Trimble KC, Douglas S, Pryde A, Heading RC (1995) Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 40: 1098–1104PubMedCrossRefGoogle Scholar
  36. [36]
    McDougall NI, Johnston BT, Kee F et al (1996) Natural history of reflux esophagitis: a 10-year follow-up of patient symptomatology and quality of life. Gut 38: 491–486Google Scholar
  37. [37]
    Isolauri J, Luostarinen M, Isolauri E et al (1997) Natural course of gastro-oesophageal reflux disease: 17–22 year follow-up of 60 patients. Am J Gastroenterol 92: 37–41PubMedGoogle Scholar
  38. [38]
    McDougall NI, Johnston BT, Collins JS et al (1997) Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol 9: 1161–1167PubMedGoogle Scholar
  39. [39]
    McDougall NI, Johnston BT, Collins JS et al (1998) Three to 4.5 year prospective study of prognostic indicators in gastro-oesophageal reflux disease. Scand J Gastroenterol 33: 1016–1022PubMedCrossRefGoogle Scholar
  40. [40]
    Fockens P (2002) Future developments in endoscopic imaging. Best Pract Res Clin Gastroenterol 16: 999–1012PubMedCrossRefGoogle Scholar
  41. [41]
    Klesslich R, Kanzler S, Vieth M, Moehler M, Neidig J, Thanka Nadar BJ, Schilling D, Burg J, Nafe B, Neurath MF, Galle PR (2004) Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis 22: 221–227CrossRefGoogle Scholar
  42. [42]
    Pehlivanov N, Liu J, Mittal RK (2001) Sustained esophageal contraction: a motor correlate of heartburn. Am J Physiol 281: G743–G751Google Scholar
  43. [43]
    Bhalla V, Liu J, Puckett JL, Mittal RK (2004) Symptom hypersensitivity to acid infusion is associated with hypersensitivity of esophageal contractility. Am J Physiol 287: G65–G71Google Scholar
  44. [44]
    Rhee PL, Liu J, Puckett JL, Mittal RK (2002) Measuring esophageal distension by high-frequency intraluminal ultrasound probe. Am J Physiol 283: G886–G892Google Scholar
  45. [45]
    Sifrim D, Castell D, Dent J, Kahrilas PJ (2004) Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, nonacid, and gas reflux. Gut 53: 1024–1031PubMedCrossRefGoogle Scholar
  46. [46]
    Shay S, Tutuian R, Sifrim D, Vela M, Wise J, Balaji N, Zhang X, Adhami T, Murray J, Castell D (2004) Twenty-four ambulatory simultaneous impedance and pH monitoring; a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 99: 1037–1043PubMedCrossRefGoogle Scholar
  47. [47]
    Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO (2001) Simultaneous intraseophageal impedance and pH measurement of acid and non-acid gastroesophageal reflux: effect of omeprazole. Gastroenterology 120: 1862–1864CrossRefGoogle Scholar
  48. [48]
    Kern M, Hofmann C, Hyde J, Shaker R (2004) Characterization of the cerebral cortical representation of heartburn in GERD patients. Am J Physiol 286: G174–G181Google Scholar
  49. [49]
    Rodriguez-Stanley S, Ciociola AA, Zubaidi S, Proskin HM, Miner PB Jr (2004) A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn. Aliment Pharmacol Ther 20: 975–982PubMedCrossRefGoogle Scholar
  50. [50]
    Frazzoni M, De Micheli E, Zentilin P, Savarino V (2004) Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 20: 81–88PubMedCrossRefGoogle Scholar
  51. [51]
    Quigley EMM (2001) Non-Erosive Reflux Disease (NERD); part of the spectrum of gastro-oesophageal reflux, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 13(Suppl 13): S13–S18PubMedGoogle Scholar
  52. [52]
    Talley NJ, Meineche-Schmidt V, Pare P, Raisanen P, Pap A, Kordecki H et al (1998) Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 12: 1055–1065PubMedCrossRefGoogle Scholar
  53. [53]
    Carlsson R, Dent J, Bolling-Sternevald E, Johnsson F, Junghard O, Lauritsen K et al (1998) The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal disease. Scand J Gastroenterol 33: 1023–1029PubMedCrossRefGoogle Scholar
  54. [54]
    Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GNJ (1999) Functional gastroduodenal disorders. Gut 45(Suppl II): II37–II42PubMedCrossRefGoogle Scholar
  55. [55]
    Mittal R, Holloway R, Penagini R, Plackshaw LA, Dent J (1995) Transient lower esophageal sphincter relaxation. Gastroenterology 109: 601–610PubMedCrossRefGoogle Scholar
  56. [56]
    Tack J, Piessevaux H, Coulie B et al (1998) Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 115: 1346–1352PubMedCrossRefGoogle Scholar
  57. [57]
    Penagini R, Hebbard G, Horowitz M et al (1998) Motor functions of the proximal stomach and visceral perception in gastro-oesophageal reflux disease. Gut 42: 251–257PubMedCrossRefGoogle Scholar
  58. [58]
    Vu MK, Straathof JWA, van der Schaar PJ, Arndt JW, Ringers J, Lamers CBHW, Masclee AAM (1999) Motor and sensory function of the stomach in reflux disease and after laparoscopic Nissen fundoplication. Am J Gastroenterol 94: 1481–1490PubMedCrossRefGoogle Scholar
  59. [59]
    Galmiche JP, Barthelmy P, Hamelin B (1997) Treating the symptoms of gastroesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Therap 11: 765–773CrossRefGoogle Scholar
  60. [60]
    Castell DO, Sigmund C Jr, Patterson D, Lambert R, Hasner D, Clyde C, Zeldis JB (1998) and the CISUSA-52 Investigator Group. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. Am J Gastroenterol 93: 547–552PubMedCrossRefGoogle Scholar
  61. [61]
    Lagergren J, Bergstrom R, Lindgren A, Nyren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340: 825–831PubMedCrossRefGoogle Scholar
  62. [62]
    van Pinxteren B, Numans ME, Bonis PA, Lau J (2000) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastrooesophageal reflux disease-like symptoms and endoscopy-negative reflux disease (Cochrane Review). In: The Cochrane Library, vol. 4. Oxford: Update SoftwareGoogle Scholar
  63. [63]
    Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J (2000) Efficacy of Omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 160: 1810–1816PubMedCrossRefGoogle Scholar
  64. [64]
    Bate CM, Keeling PWN, Axon ATR, Dronfield MW, Chapman RWG, O’Donoghue D, Calam J, Crowe J, Mountford RA, Watts DA, Taylor MD, Richardson PDI (1996) Reflux symptom relief with omeprazole inpatients without unequivocal oesophagitis. Aliment Pharmacol Ther 10: 547–555PubMedCrossRefGoogle Scholar
  65. [65]
    Bate CM, Green JRB, Axon ATR, Murray FE, Tidesley G, Emmas CE, Taylor MD (1997) Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 11: 755–763PubMedCrossRefGoogle Scholar
  66. [66]
    Carlsson R, Dent J, Watts et al (1998) Gastrooesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 10: 119–124PubMedGoogle Scholar
  67. [67]
    Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML (1997) Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 32: 965–973PubMedCrossRefGoogle Scholar
  68. [68]
    Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R (2004) Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2: 656–664PubMedCrossRefGoogle Scholar
  69. [69]
    Sontag SJ, Hirschowitz BI, Holt S, Robinson MG, Behar J, Berenson MM, McCullogh A, Ippoliti AF, Richter JE, Ahtaridis G et al (1992) Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. multicenter study. Gastroenterology 102: 109–118PubMedGoogle Scholar
  70. [70]
    Hungin APS, Gunn SD, Bate CM, Turbitt ML, Wilcock C, Richardson PDI (1993) A comparison of the efficacy of omeprazole 20 mg once daily with ranitidine 150 mg bd in the relief of symptomatic gastro-oesophageal reflux in general practice. Br J Clin Res 4: 73–88Google Scholar
  71. [71]
    Spechler SJ and the Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group (1992) Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. N Engl J Med 326: 786–792PubMedCrossRefGoogle Scholar
  72. [72]
    Vigneri S, Termini R, Leandro G et al (1995) A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333: 1106–1110PubMedCrossRefGoogle Scholar
  73. [73]
    Glise H (1995) Quality of life and cost of therapy in reflux disease. Scand J Gastroenterol 30(Suppl 210): 38–42Google Scholar
  74. [74]
    Bardhan KD, Muller-Lissner S, Bigard MA, Porro GB, Ponce J, Hosie J, Scott M, Weir DG, Gillon KRW, Peacock RA, Fulton C (1999) Symptomatic gastrooesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study. Br Med J 318: 502–507Google Scholar
  75. [75]
    Lind T, Havelund T, Lundell L, Glise H, Lauritsen K, Pedersen SA, Anker-Hansen O, Stubberod A, Eriksson G, Carlsson R, Junghard O (1999) On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis — a placebo-controlled randomized trial. Aliment Pharmacol Therap 13: 907–914CrossRefGoogle Scholar
  76. [76]
    Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, Lundell L, Pedersen SA, Carlsson R, Junghard O, Stubberod A, Anker-Hansen O (1999) Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 94: 1782–1789PubMedCrossRefGoogle Scholar
  77. [77]
    Bytzer P (2001) On-demand therapy for gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 13(Suppl 1): S19–S22PubMedGoogle Scholar
  78. [78]
    Campos GM, Peters JH, DeMeester TR, Oberg S, Crookes PF, Tan S, DeMeester SR, Hagen JA, Bremner CG (1999) Multivariate analysis of factors predicting outcome after laparoscopic fundoplication. J Gastrointest Surg 3: 292–300PubMedCrossRefGoogle Scholar
  79. [79]
    Eubanks TR, Omelanczuk P, Richards C, Pohl D, Pellegrini CA (2000) Outcomes of laparoscopic antireflux procedures. Am J Surg 179: 391–395PubMedCrossRefGoogle Scholar
  80. [80]
    Vu MK, Ringers J, Arndt JW, Lamers CB, Masclee AA (2000) Prospective study of the effect of laparoscopic hemifundoplication on motor and sensory function of the proximal stomach. Br J Surg 87: 338–343PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2006

Authors and Affiliations

  • E. M. M. Quigley
    • 1
  1. 1.Head of the Medical SchoolNational University of IrelandCorkIreland

Personalised recommendations